No Detail Found!

Imatinib in Chronic Myeloid Leukemia: Patient-reported Side Effects and Their Influence on Quality of Life.

Author(s)
Faisal Mehmood Combined Military Hospital/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Mansoor Zeeshan Combined Military Hospital/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Muhammad Umair Combined Military Hospital/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Nayab Khan Combined Military Hospital/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Abdul Ali Wajid Combined Military Hospital/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Amaira Ali Combined Military Hospital/ National University of Medical Sciences (NUMS) Rawalpindi, Pakistan
Abstract
Objective: To evaluate side effects of Imatinib by patients of chronic myeloid leukemia and their influence on quality of life. Study Design: Descriptive & analytic study. Place and Duration of Study: The study was carried out at department of oncology CMH Rawalpindi, from Jan 2015 to Dec 2015. Material and Methods: The study was carried out at department of oncology CMH Rawalpindi from Jan 2015 to Dec 2015. Patients who had been using Imatinib orally for at least 6 months participated in the study. Patients under 18 years of age were excluded from the study. A questionnaire was developed to record adverse effects. This questionnaire included demographic details and quality of life issues like effects on their mood, daily life activities, work, walking and relationships. Results: Ninety two patients participated in the study. Mean age of the participants was 42.05 years (range 22 to 68 years), 52% were males. Among the study population eighty-seven percent had suffered from at least one adverse reaction. The most commonly complained adverse events were muscle cramps (67 out of 92, 72.8%); fatigue (58 out of 92 63.04%), gastro intestinal upset (44 out of 92 47.82%) and skin rashes (30 out of 92 32.60%). More than half of the patients felt that the adverse effect had a negative influence on their daily quality of life. Conclusion: Adverse drug effects were common among CML patients receiving Imatinib therapy. These adverse drug reactions had negative impact on patients' daily life.
Publication Details
Page(s) 466-470
DOI DOI not available
Published Journal: Pakistan Armed Forces Medical Journal, Volume: 68, Issue: 3, Year: 2018

Request the full text from PASTIC

References
SiegelRL,MillerKD,JemalA, 2015.,CA Cancer J Clin 65 5 -29
EganD,RadichJ, 2016.Making the diagnosis, the tools, and risk stratification: More than just BCR-ABL,Best Pract Res Clin Haematol 29 252 -63
QinYZ,HuangXJ, 2016.Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia,Methods Mol Biol 1465 1 -15
DeiningerMW,O'BrienSG,GuilhotF, 2009.International randomized study of interferon vs STI571 (IRIS) 8-year followup: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract 1126],Blood 114 -
CaldemeyerL,DuganM,EdwardsJ,AkardL, 2016.Long-Term Side Effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia,Curr Hematol Malig Rep 11 71 -9
HochhausA,O'BrienSG,GuilhotF, 2009.Six-year follow-up of patients receiving imatinib for the firstline treatment of chronic myeloid leukemia,Leukemia 23 1054 -61
7 Van HunselF,HärmarkL,PalS,OlssonS,van GrootheestK., 2012.Experiences with adverse drug reaction reporting by patients: an 11-country survey,Drug Saf 35 45 -60
TraskPC,CellaD,PowellC, 2013.Health related quality of life in chronic myeloid leukemia,Leuk Res 37 9 -13
FoodDrug, 2009.Administration: Guidance for Industry. Patientreported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, -
10 XiaoC,PolomanoR,BrunerDW, 2013.Comparison between patientreported and clinician-observed symptoms in oncology,Cancer Nurs 36 E1 -E16
JabbourE,SaglioG,RadichJ,KantarjianH, 2012.Adherence to BCRABL inhibitors: issues for CML therapy,Clin Lymphoma Myeloma Leuk 12 223 -29
MeriK,MarikkiP,MarjaA, 2015.Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment,Patient Prefer Adherence 9 1733 -40
USFood Drug, 2009.Administration: Guidance for Industry. Patientreported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, -
GanesanP,SagarTG,DubashiB, 2011.Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia,Am J Hematol 86 471 -4
0

Citations

0

Downloads

52

Views